Direct medical costs of breast cancer in Jordan: cost drivers and predictors

Mousa, Rimal; Hammad, Eman A.; Melhem, Jamal Masad; Al-Jaghbir, Madi T.

doi:10.1080/14737167.2021.1859372

Cited by 8 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we found that medication costs increased substantially with advancing cancer stages, representing 33.5%, 57.4%, 62.4%, and 80.4% of the cost at stages I, II, III, and IV, respectively. These findings were similar to those of previously reported studies across different countries, in which medication costs were identified as the main cost drivers for all disease stages [ 24 , 25 , 26 ].…”

Section: Discussionsupporting

confidence: 92%

“…This supports the outcomes of a previous study that identified targeted therapy drugs as major contributors to medication-related spending on breast cancer patients in Saudi Arabia [ 27 ]. This is also the case in other Middle East and North Africa (MENA) countries such as Jordan, where the total cost of trastuzumab accounted for almost 80.0% of medication costs evaluated in one study, and Morocco, where one course of trastuzumab can amount to as much as 60 times the cost of certain other chemotherapy drugs [ 25 , 28 ]. In the US, the use of targeted therapies has reportedly steadily increased over the last 10 years, with major economic impact, mainly attributable to higher drug prices [ 29 ].…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

et al. 2021

View full text Add to dashboard Cite

Globally, breast cancer management is associated with a heavy economic burden, but its impact in Saudi Arabia has not been fully quantified. The aim of this study was to estimate the economic burden of breast cancer management at various disease stages, in Saudi Arabia, from a payer perspective. We conducted a retrospective, multicenter cost of illness study in two governmental healthcare centers from January to December 2018, using the data of 300 patients at different breast cancer stages. A micro-costing, bottom-up method was used, and descriptive and inferential statistics were analyzed. The total estimated cost for treating breast cancer during the study period was $13.345 million USD, with the average cost per patient ranging from $14,249 USD in stage I to $81,489 USD in stage IV (p < 0.001). Medication cost was the main driver of total healthcare spending, followed by hospitalization and diagnostic tests. The cost of targeted therapy drugs represented 67% of the total medication costs, mostly driven by trastuzumab-based regimens. The economic burden of breast cancer management in Saudi Arabia is substantial and increases significantly with disease advancement. Early detection screening programs, evaluating the value of highly expensive interventions, and considering biosimilars, may contribute toward cost savings.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 89%

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Moreover, the cost of managing metastatic patients was 2.8 times higher compared to non-metastatic patients. A study by Mousa et al (2020) that was conducted on breast cancer patients in Jordan reported that costs increased in the advanced stages of the disease, with stage 4 patients paying 61.0 % more than stage 1 patients ( Mousa 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical and therapeutic characteristics and medical cost of managing cancer patients in Al-Anbar, Iraq: A cross-sectional study

Hameed

Naser²,

Talib³

2022

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

“… 6 In addition, the treatment costs of some cancer types, such as breast cancer, surged significantly in the late disease stages in Jordan. 7 8 …”

Section: Introductionmentioning

confidence: 99%

“…For instance, in the Kingdom of Jordan, the incidence and mortality rates of cancer are rapidly increasing; between 2000 and 2013, the average crude cancer incidence rate in Jordan was 82.8/100 000 population,5 while in 2016, the crude incidence rate increased to 87.2/100 000 population 6. In addition, the treatment costs of some cancer types, such as breast cancer, surged significantly in the late disease stages in Jordan 7 8…”

Section: Introductionmentioning

confidence: 99%

Unravelling the predictors of late cancer presentation and diagnosis in Jordan: a cross-sectional study of patients with lung and colorectal cancers

et al. 2023

View full text Add to dashboard Cite

ObjectivesLate presentation or diagnosis of cancer results in a poor clinical prognosis, negatively affects treatment and subsequently lowers one’s chances of survival. This study aimed to identify the factors associated with late lung and colorectal cancer presentation and diagnosis in Jordan.DesignThis correlational cross-sectional study was based on face-to-face interviews and medical chart reviews from a cancer registry database. A structured questionnaire based on a review of the literature was used.Setting and participantsThe study participants were a representative sample of adult patients with colorectal or lung cancer who visited the outpatient clinics at King Hussein Cancer Center in Amman, Jordan, between January 2019 and December 2020, to get their first medical consultation.Results382 study participants were surveyed, with a response rate of 82.3%. Of these, 162 (42.2%) reported a late presentation and 92 (24.1%) reported a late diagnosis of cancer. The results of backward multivariate logistic regression analyses showed that female gender and not seeking a medical advice when feeling ill combined was associated with an almost three times increased likelihood of reporting a late presentation with cancer (adjusted OR 2.97, 95% CI 1.19 to 7.43). Not having health insurance and not seeking medical advice combined was also associated with late presentation (2.5, 95% CI 1.02 to 6.12). For lung cancer, Jordanians living in rural areas were 9.29 (95% CI 2.46 to 35.1) times more likely to report late diagnosis. Jordanians who did not screen for cancer in the past were 7.02 (95% CI 1.69 to 29.18) times more likely to report late diagnosis. For colorectal cancer, those having no previous knowledge about cancers or screening programmes had increased odds of reporting late diagnosis (2.30, 95% CI 1.06 to 4.97).ConclusionsThis study highlights important factors associated with the late presentation and diagnosis of colorectal and lung cancers in Jordan. Investing in national screening and early detection programmes as well as public outreach and awareness campaigns will have a significant impact on early detection to improve treatment outcomes.

show abstract

Direct medical costs of breast cancer in Jordan: cost drivers and predictors

Cited by 8 publications

References 23 publications

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

Clinical and therapeutic characteristics and medical cost of managing cancer patients in Al-Anbar, Iraq: A cross-sectional study

Unravelling the predictors of late cancer presentation and diagnosis in Jordan: a cross-sectional study of patients with lung and colorectal cancers

Contact Info

Product

Resources

About